Breaking News, Collaborations & Alliances

Ligand Earns Milestone for Kyprolis Sales

Receives $1 million commercial milestone payment from Onyx

Ligand Pharmaceuticals, Inc. has earned $1 million commercial milestone payment from Onyx Pharmaceuticals, a subsidiary of Amgen, triggered by the achievement of more than $250 million of annual product sales of Kyprolis in 2013.
 
Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones. Kyprolis is indicated to treat multiple myeloma and was received accelerated approval from FDA in July 2012.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters